Ravgen, Inc. v. Laboratory Corporation of America Holdings

District Court, W.D. Texas·Decided January 23, 2025·No. 6:20-cv-00969·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS WACO DIVISION

RAVGEN, INC., § Civil A§ ction No. 6:20-cv-00969-ADA Plaintiff § § -v- JURY§ TRIAL DEMANDED § LABORATORY CORPORATION § OF AMERICA HOLDINGS, § § Defendant §

MEMORANDUM OPINION AND ORDER GRANTING-IN-PART PLAINITIFF’S MOTION TO AMEND THE JUDGMENT TO INCLUDE SUPPLEMENTAL DAMAGES, PRE-JUDGMENT INTEREST, AND POST-JUDGMENT INTEREST, AND TO ADJUDGE CLAIM 132 NOT INVALID (ECF NO. 238) Before the Court is Plaintiff Ravgen, Inc.’s (“Ravgen’s”) Motion to Amend the Judgment to Include Supplemental Damages, Pre-Judgment Interest, and Post-Judgment Interest, and to Adjudge Claim 132 Not Invalid (ECF No. 238). Defendant Laboratory Corporation of America Holdings (“Labcorp”) filed an opposition to the motion on October 27, 2022 (ECF No. 250) and Ravgen filed a reply on November 3, 2022 (ECF No. 269). After careful consideration of the motion, the parties’ briefing, and the applicable law, the Court GRANTS-IN-PART Ravgen’s motion. I. BACKGROUND Ravgen brought a patent infringement suit against Labcorp on October 16, 2018, alleging infringement of U.S. Patent No. 7,332,277 (“the ’277 patent”), inter alia. See ECF No. 1. The ’277 patent is directed to methods of detection of genetic disorders. Id. at 11. Ravgen alleged that Labcorp manufactures, provides, sells, offers for sale, imports, and/or distributes products and services directly infringing the ’277 patent. Id. at 57, 66. This Court conducted a jury trial on September 19–23, 2022, resulting in a unanimous verdict that Labcorp infringed the’277 patent. ECF No. 222 at 3. II. LEGAL PRINCIPLES A. Supplemental Damages “Under 35 U.S.C. §284, upon a finding of infringement, a prevailing ‘patentee is entitled

to damages for the entire period of infringement and should therefore be awarded supplemental damages for any periods of infringement not covered by the jury verdict.’” Jiaxing Super Lighting Elec. Appliance Co. v. CH Lighting Tech. Co., No. 6:20-CV-00018-ADA, 2023 WL 2415281, at *18 (W.D. Tex. Mar. 8, 2023) (quoting ActiveVideo Networks, Inc. v. Verizon Commc’ns, Inc., No. 2:10-cv-248, 2011 WL 4899922, at *1 (E.D. Va. Oct. 14, 2011)). “[S]upplemental damages are compensatory in nature and calculated in accordance with the damages awarded in the jury verdict.” Id. The Court has “discretion to award damages for periods of infringement not considered by the jury.” Whitserve, LLC v. Computer Packages, Inc., 694 F.3d 10, 38 (Fed. Cir. 2012). B. Ongoing Royalty It is within the Court’s equitable discretion to determine whether an ongoing royalty need

be imposed. See Paice LLC v. Toyota Motor Corp., 504 F.3d 1293, 1314–15 (Fed. Cir. 2007). Although an ongoing royalty is not automatic, “the Federal Circuit has indicated that a prevailing patentee should receive compensation for any continuing infringement.” Apple, Inc. v. Samsung Elecs. Co., No. 12-cv-00630-LHK, 2014 WL 6687122, at *7 (N.D. Cal. Nov. 25, 2014) (citing Telcordia Techs., Inc. v. Cisco Sys., Inc., 612 F.3d 1365, 1379 (Fed. Cir. 2010)). In determining the ongoing royalty rate, the Court must consider: (i) the “change in the parties’ bargaining positions, and the resulting change in economic circumstances, resulting from 2 the determination of liability”; (ii) “changed economic circumstances, such as changes related to the market for the patented products”; and (iii) any other “post-verdict factor” that would impact “what a hypothetical negotiation would look like after the prior infringement verdict.” XY, LLC v. Trans Ova Genetics, L.C., 890 F.3d 1282, 1297 (Fed. Cir. 2018). “Generally, the jury’s damages award is a starting point for evaluating ongoing royalties.” Apple, Inc., 2014 WL 6687122, at *14

(citing Bard Peripheral Vascular, Inc. v. W.L. Gore & Assocs., Inc., 670 F.3d 1171, 1193 (Fed. Cir. 2012), vacated on other grounds, 467 F. App’x 747). In addition, the Court may consider the Georgia-Pacific factors. Arctic Cat Inc. v. Bombardier Recreational Prods. Inc., 876 F.3d 1350, 1370 (Fed. Cir. 2017). C. Prejudgment Interest A damages award should provide “complete compensation,” Gen. Motors Corp. v. Devex Corp., 461 U.S. 648, 655 (1983), including “a reasonable royalty for the use made of the invention by the infringer, together with interest and costs. 35 U.S.C. § 284. “The purpose of prejudgment interest is to place the patentee in as good a position as he would have been had the infringer paid a reasonable royalty rather than infringe.” SSL Servs., LLC v. Citrix Sys., Inc., 769 F.3d 1073, 1094

(Fed. Cir. 2014). “The award of pre-judgment interest is the rule, not the exception.” Energy Transp. Grp., Inc. v. William Demant Holding A/S, 697 F.3d 1342, 1358 (Fed. Cir. 2012). But Section 284 does not “requir[e] the award of prejudgment interest whenever infringement is found.” Devex, 461 U.S. at 65–56. III. ANALYSIS A. Ravgen is Entitled to Post-Verdict Supplemental Damages Ravgen moves for post-verdict supplemental damages for infringement from September 23, 2022 through October 5, 2022. ECF No. 238 at 2. Ravgen seeks a royalty rate of $100-per-test. 3 Id. at 2–3. For the period between the verdict and entry of the judgment (September 23, 2022 through October 5, 2022), Ravgen seeks $1,929,600 based on Labcorp’s averages sales per day for 2022 of 1,608 tests. Id. at 3. Labcorp does not dispute that Ravgen is entitled to this amount for post-judgment damages. ECF No. 250 at 1. Ravgen also requests that the Court enhance the royalty rate by the same amount that the

Court enhances the jury award for willful infringement. ECF No. 238 at 3–4. Labcorp does not provide any arguments against enhancing the post-verdict supplemental damages except the arguments presented in opposition to Ravgen’s Motion for Enhanced Damages. ECF No. 250 at 1. In the Memorandum Opinion and Order Granting-In-Part Plaintiff’s Motion for Enhanced Damages (ECF No. 232) and Awarding Enhanced Damages, the Court declined to award Ravgen full treble damages and instead awarded Ravgen enhanced damages in the amount of $100,000,000. ECF No. 303. The enhanced damages award adds $36.70 to the royalty rate of each test. The Court awards Ravgen the same amount of enhanced damages ($36.70 per test) for post- verdict supplemental damages, which totals an additional $708,163.20.

Therefore, the Court finds that Ravgen is entitled to $2,637,763.20 in post-verdict supplemental damages. B. Ravgen is Entitled to an Ongoing Royalty in the Amount of $100 Per Infringing Test Ravgen seeks an ongoing royalty from October 5, 2022 through the expiration of the ’277 Patent in the amount of $147.50 for every infringing test. ECF No. 238 at 4. Labcorp opposes an ongoing royalty rate higher than the rate awarded by the jury. ECF No. 250 at 2.

Free access — add to your briefcase to read the full text and ask questions with AI

Ravgen, Inc. v. Laboratory Corporation of America Holdings, (W.D. Tex. 2025).

Ravgen, Inc. v. Laboratory Corporation of America Holdings (Ravgen, Inc. v. Laboratory Corporation of America Holdings) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

General Motors Corp. v. Devex Corp.
461 U.S. 648 (Supreme Court, 1983)
Telcordia Technologies, Inc. v. Cisco Systems, Inc.
612 F.3d 1365 (Federal Circuit, 2010)
Paice LLC v. Toyota Motor Corp.
504 F.3d 1293 (Federal Circuit, 2007)
United States v. Jose Rodriguez-Arroyo
467 F. App'x 746 (Ninth Circuit, 2012)
Whitserve, LLC v. Computer Packages, Inc.
694 F.3d 10 (Federal Circuit, 2012)
Georgia-Pacific Corp. v. United States Plywood Corp.
318 F. Supp. 1116 (S.D. New York, 1970)
Ssl Services, LLC v. Citrix Systems, Inc.
769 F.3d 1073 (Federal Circuit, 2014)
Xy, LLC v. Trans Ova Genetics, L.C.
890 F.3d 1282 (Federal Circuit, 2018)